BIOMAT Database Logo BIOMAT Database Logo

Androgen deprivation therapy for prostate cancer. 2008

Eric A Singer, and Dragan J Golijanin, and Hiroshi Miyamoto, and Edward M Messing
Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA.

Androgen deprivation continues to play a crucial role in the treatment of advanced and metastatic prostate cancer. In the 65 years since its use was first described, urologists and medical oncologists have developed new and innovative ways to manipulate the hypothalamic-pituitary-gonadal axis with the goal of alleviating symptoms and prolonging the life of men with prostate cancer. Despite the successes that androgen deprivation therapy has brought, each method and regimen possesses unique benefits and burdens, of which the clinician and patient must be cognizant. This review discusses the first-line androgen deprivation methods and regimens presently in use with special attention paid to their side effects and the management of them, as well as the question of when to initiate androgen deprivation therapy.

UI MeSH Term Description Entries
D008297 Male Males
D009919 Orchiectomy The surgical removal of one or both testicles. Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D011468 Prostatectomy Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE). Prostatectomy, Retropubic,Prostatectomy, Suprapubic,Prostatectomies,Prostatectomies, Retropubic,Prostatectomies, Suprapubic,Retropubic Prostatectomies,Retropubic Prostatectomy,Suprapubic Prostatectomies,Suprapubic Prostatectomy
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000726 Androgen Antagonists Compounds which inhibit or antagonize the biosynthesis or actions of androgens. Androgen Antagonist,Antiandrogen,Antiandrogens,Anti-Androgen Effect,Anti-Androgen Effects,Antiandrogen Effect,Antiandrogen Effects,Antagonist, Androgen,Antagonists, Androgen,Anti Androgen Effect,Anti Androgen Effects,Effect, Anti-Androgen,Effect, Antiandrogen,Effects, Anti-Androgen,Effects, Antiandrogen
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Eric A Singer, and Dragan J Golijanin, and Hiroshi Miyamoto, and Edward M Messing
Androgen Deprivation Therapy for Prostate Cancer.
January 2018, Advances in experimental medicine and biology,
Eric A Singer, and Dragan J Golijanin, and Hiroshi Miyamoto, and Edward M Messing
Androgen-deprivation therapy for prostate cancer.
June 2003, Clinical prostate cancer,
Eric A Singer, and Dragan J Golijanin, and Hiroshi Miyamoto, and Edward M Messing
Androgen deprivation therapy for prostate cancer.
October 2017, The Lancet. Oncology,
Eric A Singer, and Dragan J Golijanin, and Hiroshi Miyamoto, and Edward M Messing
Androgen deprivation therapy for prostate cancer.
July 2005, JAMA,
Eric A Singer, and Dragan J Golijanin, and Hiroshi Miyamoto, and Edward M Messing
Androgen deprivation therapy for prostate cancer.
October 2007, The Journal of urology,
Eric A Singer, and Dragan J Golijanin, and Hiroshi Miyamoto, and Edward M Messing
Intermittent androgen deprivation therapy for prostate cancer.
January 2004, The oncologist,
Eric A Singer, and Dragan J Golijanin, and Hiroshi Miyamoto, and Edward M Messing
Complications of androgen deprivation therapy for prostate cancer.
May 2004, Current opinion in urology,
Eric A Singer, and Dragan J Golijanin, and Hiroshi Miyamoto, and Edward M Messing
Advances with androgen deprivation therapy for prostate cancer.
June 2022, Expert opinion on pharmacotherapy,
Eric A Singer, and Dragan J Golijanin, and Hiroshi Miyamoto, and Edward M Messing
Osteoporosis during androgen deprivation therapy for prostate cancer.
September 2002, Urology,
Eric A Singer, and Dragan J Golijanin, and Hiroshi Miyamoto, and Edward M Messing
miRNAs and androgen deprivation therapy for prostate cancer.
December 2021, Biochimica et biophysica acta. Reviews on cancer,
Copied contents to your clipboard!